Angie You
About Angie You
Angie You, Ph.D., age 52 as of March 31, 2025, has served on ORIC’s board since November 2021 and is nominated to continue as a Class II director through 2028. She is CEO and a director of Architect Therapeutics (since March 2023), previously CEO of Amunix (2018–2022, acquired by Sanofi), and held senior commercial roles at Sierra Oncology (2014–2018). She earned an A.B. in Chemistry and a Ph.D. in Biochemistry from Harvard University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Architect Therapeutics, LLC | Chief Executive Officer; Director | Mar 2023–present | CEO leadership; board service |
| Amunix Pharmaceuticals, Inc. | Chief Executive Officer | Dec 2018–Jan 2022 | Led company through acquisition by Sanofi |
| Sierra Oncology, Inc. | Chief Business & Strategy Officer; Head of Commercial | Sep 2014–Dec 2018 | Led strategic/transactional business and commercial efforts; supported IPO |
| Casdin Capital | Advisor | Apr 2022–May 2023 | Strategic advisory |
| Frasier Healthcare | Senior Advisor | Feb 2022–present | Strategic advisory |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Candid Therapeutics, Inc. | Director | Oct 2024–present | Board service |
| Attovia Therapeutics | Director | Jul 2024–present | Board service |
| RayzeBio, Inc. | Director | Apr 2022–Mar 2024 | Prior public company board |
| Architect Therapeutics, LLC | Director | Mar 2023–present | Interlock: ORIC Chair Richard Heyman is also on Architect’s board |
Board Governance
- Committee assignments: Audit Committee member; Nominating & Corporate Governance Committee member .
- Independence: Board determined Dr. You is independent under Nasdaq rules; audit and compensation committees composed of independent directors .
- Attendance: In 2024, each director attended at least 75% of board and assigned committee meetings; ORIC held 4 board meetings; Audit Committee held 4; Compensation Committee held 5; Nominating & Corporate Governance Committee held 3 .
- Anti-hedging/pledging: Policy prohibits directors from hedging, pledging, short sales, and trading derivative securities on ORIC stock .
Fixed Compensation
| Component | Amount (USD) | Basis |
|---|---|---|
| Annual board retainer | $40,000 | Director compensation policy |
| Audit Committee member fee | $7,500 | Director compensation policy |
| Nominating & Corporate Governance Committee member fee | $5,000 | Director compensation policy |
| Total cash paid to Angie You (2024) | $52,500 | Reported director cash fees (2024) |
Additional policy features:
- Chair fees: Audit Chair $15,000; Compensation Chair $10,000; Nominating & Corporate Governance Chair $10,000; Chair does not also receive member fee .
- Annual cap: $500,000 per year in cash + equity for non-employee directors; $750,000 in the year joining the board (equity valued at grant-date fair value per GAAP) .
Performance Compensation
| Award Type | Grant Size | Vesting | Change-in-Control | Notes |
|---|---|---|---|---|
| Annual stock option award (pre-Dec 2024 policy) | 25,600 shares | Prior awards vest in full by next AGM or 1-year from grant; beginning 2025, 1/12 monthly | Full vest immediately prior to consummation | Exercise price = fair market value; 10-year term |
| Annual stock option award (2025 policy) | 35,000 shares | 1/12 monthly from grant date (Jan cycle) | Full vest immediately prior to consummation | Policy updated Dec 12, 2024 |
| Initial stock option award (pre-Dec 2024 policy) | 51,200 shares | 1/36 monthly from start of service | Full vest immediately prior to consummation | — |
| Initial stock option award (2025 policy) | 70,000 shares | 1/36 monthly from start of service | Full vest immediately prior to consummation | “Change in control” definition aligned with 2020 Plan |
2024 equity awarded to Angie You:
- Option awards grant-date fair value: $146,150 (includes annual option and director retention option awards in 2024) .
Other Directorships & Interlocks
| Relationship | Detail | Potential Consideration |
|---|---|---|
| Interlock with ORIC Chair | Both Angie You and Richard Heyman serve on Architect Therapeutics’ board | Information flow/overboarding considerations; still independent under Nasdaq rules |
| Large shareholder linkage (context) | Entities affiliated with Frazier Life Sciences hold >5% of ORIC; Dr. You has been a senior advisor to “Frasier Healthcare” | Monitor for perceived network ties; audit committee reviews related party transactions; no transactions disclosed |
Expertise & Qualifications
- Drug development and commercial strategy expertise; prior CEO experience; public company director experience .
- Audit Committee service; not designated as audit committee financial expert (that role is held by Audit Chair Mardi Dier) .
Equity Ownership
| As-of Date | Direct Common Shares | Options Exercisable within 60 days | Total Beneficial Ownership | % of Outstanding Shares |
|---|---|---|---|---|
| Mar 31, 2025 | 0 | 109,651 | 109,651 | <1% |
Additional equity context:
- Outstanding option awards held by Angie You as of Dec 31, 2024: 124,508 shares (aggregate across awards) .
- Company policy prohibits hedging/pledging of company securities .
Insider Trades
| Date | Transaction | Shares | Price | Source |
|---|---|---|---|---|
| Jun 20, 2025 | Open-market purchase | 26,597 | $9.3871 weighted avg (range $9.14–$9.50) | |
| Jun 23, 2025 | Open-market purchase | 1,403 | $9.43 |
- Following these transactions, reported direct ownership reached 28,000 ORIC shares as of June 23, 2025 .
- Additional Form 4 filing exists on Jan 6, 2025 (issuer link), not detailed here .
Governance Assessment
- Independence and engagement: Board affirms independence; she serves on two key governance committees (audit; nom/gov). Attendance met at least the 75% threshold in 2024; committee meeting cadence supports active oversight .
- Alignment and incentives: Director pay is modest cash plus at-risk options; 2024 option grant FV = $146,150; 2025 policy increases option sizes to align with peers; recent personal share purchases (28,000 shares) bolster skin-in-the-game .
- Conflicts/related party: No related party transactions disclosed; interlocks (Architect board) and advisory ties warrant monitoring but audit committee oversees related party reviews; strict anti-hedging/pledging policy reduces alignment risk .
- Compensation structure: Cash fees consistent with committee roles; equity exclusively in stock options with single-trigger change-in-control acceleration for directors; annual compensation cap applies, limiting pay inflation risk .
Director Compensation (Context)
| Director | 2024 Cash Fees | 2024 Option Awards (FV) | Total 2024 Compensation |
|---|---|---|---|
| Angie You, Ph.D. | $52,500 | $146,150 | $198,650 |
Board Meeting Cadence (2024)
| Body | Meetings Held |
|---|---|
| Board of Directors | 4 |
| Audit Committee | 4 |
| Compensation Committee | 5 |
| Nominating & Corporate Governance Committee | 3 |
Policy Highlights
- Clawback (executives): Non-discretionary recovery of excess incentive-based compensation following accounting restatements per SEC/Nasdaq rules (executive officers) .
- Equity awards timing: Grants generally avoid periods surrounding material nonpublic information; annual equity grants aligned at the start of fiscal year (directors and executives from 2025) .
- Related party transaction review: Audit committee pre-approves any >$120,000 transactions with related persons; none reported involving directors in 2024–2025 .